Hyperhomocysteinemia and C677T MTHFR genotype in patients with retinal vein thrombosis

Clinical and Applied Thrombosis/Hemostasis

Volumn 16, Issue 5, 2010, Pages 549-553

  Sottilotta, Gianluca ^a   Siboni, Simona Maria ^b   Latella, Caterina ^a   Oriana, Vincenzo ^a   Romeo, Ermelinda ^a   Santoro, Rita ^c   Consonni, Dario ^b   Lombardo, Vincenzo Trapani ^a  

^a BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c PUGLIESE CIACCIO HOSPITAL   (Italy)

Author keywords

Gene polymorphisms; Thrombophilia; Venous thromboembolism

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); HOMOCYSTEINE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; FEMALE; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETINA VEIN THROMBOSIS; RISK FACTOR; VEIN THROMBOSIS;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POLYMORPHISM, GENETIC; RETINAL VEIN OCCLUSION; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 77955892609     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029609348644     Document Type: Article

References (23)

1. Terrazzi P., Di Micco P., Quaglia I., et al. Homocysteine, MTHFR C677T gene polymorphism, folic acid and vitamin B 12 in patient with retinal vein occlusion. Thromb J. 2005 ; 3 (Sep 7). 13.
2. Klein R., Klein B., Moss SE, Meuer SM The epidemiology of retinal vein occlusion: the beaver dam eye study. Trans Am Ophthalmol Soc. 2000 ; 98: 133-141.
3. Haas S. Low molecular weight heparins in the prevention of venous thromboembolism in nonsurgical patients. Semin Thromb Hemost. 1999 ; 25 (suppl 3). 101-105.
4. Wu-Wong JR Endothelial dysfunction and chronic kidney disease: treatment options. Curr Opin Investig Drugs. 2008 ; 9 (9). 970-982.
5. Gao W., Wang YS, Zhang P., Wang HY Hyperhomocysteinemia and low plasma folate as risk factors for central retinal vein occlusion: a case-control study in a Chinese population. Graefes Arch Clin Exp Ophthalmol. 2006 ; 244 (10). 1246-1249.
6. Cahill M., Karabatzaki M., Meleady R., et al. Raised plasma homocysteine as a risk factor for retinal vascular occlusive disease. Br J Ophthalmol. 2000 ; 84 (2). 154-157.
7. Martin SC, Rauz S., Marr JE, Martin N., Jones AF, Dodson PM Plasma total homocysteine and retinal vascular disease. Eye. 2000 ; 14 (pt 4). 590-593.
8. Vine AK Hyperhomocysteinemia: a risk factor for central retinal vein occlusion. Am J Ophthalmol. 2000 ; 129 (5). 640-644.
9. Marcucci R., Bertini L., Giusti B., et al. Thrombophilic risk factors in patients with central retinal vein occlusion. Thromb Haemostasis. 2001 ; 86 (3). 772-776.
10. Larsson J., Hultberg B., Hillarp A. Hyperhomocysteinemia and the MTHFR C677T mutation in central retinal vein occlusion. Acta Ophthalmol Scand. 2000 ; 78 (3). 340-343.
11. Boyd S., Owens D., Gin T., et al. Plasma homocysteine, methylenetetrahydrofolate reductase C677T and factor II G20210A polymorphisms, factor VIII, and VWF in central retinal vein occlusion. Br J Ophthalmol. 2001 ; 85 (11). 1313-1315.
12. McGimpsey SJ, Woodside JV, Bamford L., et al. Retinal vein occlusion, homocysteine and methylene tetrahydrofolate reductase genotype. Invest Ophthalmol Vis Sci. 2005 ; 46 (12). 4712-4716.
13. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA. 1995 ; 274 (13). 1049-1057.
14. D'Angelo A., Selhub J. Homocysteine and thrombotic disease. Blood. 1997 ; 90 (1). 1-11.
15. Ray JG Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med. 1998 ; 158 (19). 2101-2106.
16. Wirta V., Saransaari P., Wirta O., et al. Methylenetetrahydrofolate reductase gene polymorphism, hyperhomocysteinemia and occlusive retinal vascular disease in type 2 diabetic and non-diabetic subjects. Clin Nephrol. 2002 ; 58 (3). 171-178.
17. StataCorp. Stata Statistical Software: Release 10. College Station, TX: StataCorp LP ; 2007.
18. Biancardi AL, Gadelha T., Borges WI, Vieira de Moraes H. Jr, Spector N. Thrombophilic mutations and risk of retinal vein occlusion. Arq Bras Oftalmol. 2007 ; 70 (6). 971-974.
19. Weger M., Stanger O., Deutschmann, et al. Hyperhomocyst(e)inemia and MTHFR C677T genotypes in patients with central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2002 ; 240 (4). 286-290.
20. Abbate R., Sardi I., Pepe G., et al. The high prevalence of thermolabile 5-10 methylenetetrahydrofolate reductase (MTHFR) in Italians is not associated to an increased risk for coronary artery disease (CAD). Thromb Haemost. 1998 ; 79 (4). 727-730.
21. Aucella F., Margaglione M., Grandone E., et al. The C677T methylenetetrahydrofolate reductase gene mutation does not influence cardiovascular risk in the dialysis population: results of a multi-centre prospective study. Nephrol Dial Transplant. 2005 ; 20 (2). 382-386.
22. Wilcken DE, Wilcken B. The natural history of vascular disease in homocystinuria and the effects of treatment. J Inherit Metab Dis. 1997 ; 20 (2). 295-300.
23. Peterson JC, Spence JD Vitamins and progression of atherosclerosis in hyper-homocysteinaemia. Lancet. 1998 ; 351 (9098). 263-263.